Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zynerba Pharma CS 80 W. LANCASTER AVENUE SUITE 300 DEVON PA 19333 USA

www.zynerba.com P: 484-581-7505

Sector:

Medical

INDUSTRY GROUPING:

Medical - Generic Drugs

Description:

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 70,121
Enterprise Value, $K 19,481
Shares Outstanding, K 53,939
Float, K 46,905
% Float 86.96%
Short Volume Ratio 0.31
% of Insider Shareholders 13.04%
% of Institutional Shareholders 11.23%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -35,040 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,780 K
EBIT, $ -38,790 K
EBITDA, $ -38,570 K

Growth:

1-Year Return 85.77%
3-Year Return -66.23%
5-Year Return -80.85%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 66.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.21 on 08/14/23
Next Earnings Date 11/13/23
Earnings Per Share ttm -0.80
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 12.50%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ZYNE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -90.03%
Return-on-Assets % -72.62%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.40
Book Value/Share 0.54
Interest Coverage 0.00
60-Month Beta 1.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar